Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2026.1767840 Review T cell-mediated immune responses in xenotransplantation: mechanisms and therapeutic strategies WangZiyue 1 * Data curation Formal analysis Investigation Writing – original draft Writing – review & editing LiuGuomu 2 * Conceptualization Data curation Visualization Writing – review & editing Key Laboratory of Organ Regeneration & Transplantation of Ministry of Education, The First Hospital of Jilin University, Changchun, China Department of Dermatology and Venereology, The First Hospital of Jilin University, Changchun, China Correspondence: Ziyue Wang, wangzyjlu@163.com; Guomu Liu, Liuguomu5465511@jlu.edu.cn 23 02 2026 2026 17 1767840 15 12 2025 05 02 2026 05 02 2026 Copyright © 2026 Wang and Liu. 2026 Wang and Liu https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Xenotransplantation has emerged as a promising approach to alleviate the shortage of donor organs. While advances in porcine gene-editing technologies have largely overcome hyperacute rejection, the persistent challenge of T cell- and antibody-mediated rejection reactions continues to impede the long-term survival and clinical translation of xenografts. T cells connect innate and adaptive immunity and are the main effector cells in cell-mediated rejection reactions. The antigen recognition, activation, and effector differentiation of T cells have a crucial impact on the clinical outcomes of xenotransplantation. This review focuses on the immune response process of T cells in xenotransplantation and discusses potential strategies for T cell-mediated rejection reactions. Future exploration of efficient and safe approaches for inducing immune tolerance will be a key direction for prolonging the survival of xenografts.

 immunological tolerance immunosuppression T cell-mediated rejection xenoantigen xenotransplantation The author(s) declared financial support was received for this work and/or its publication. This work was supported by the Natural Science Foundation of Jilin Province (No. YDZJ202201ZYTS675). section-at-acceptance Alloimmunity and Transplantation Introduction

Transplantation remains one of the most effective therapies for end-stage organ failure (1, 2). However, the number of patients waiting for transplantation continues to rise, whereas the supply of suitable human donor organs is severely insufficient (3–5). Xenotransplantation is a promising strategy to alleviate this shortage. Pigs are regarded as particularly suitable donors due to multiple advantages (6). Pigs share similarities with humans in physiology and anatomy; moreover, they can grow rapidly and be raised on a large scale, making them an “off-the-shelf” universal product. Most importantly, pig gene editing technology is mature, allowing for multiple edits (7, 8). Additionally, the ethical considerations of using pigs as donors are more favorable compared to other species (5, 9). In recent years, the field of xenotransplantation has made rapid progress through the optimization of multi-gene editing strategies in donor pigs and immunosuppressive regimens. Currently, gene editing strategies for donors typically involve knocking out major xenogeneic carbohydrate antigens (GGTA1, CMAH, B4GALNT2), while introducing human complement regulatory proteins (hDAF, hCD46, hCD59), coagulation regulatory molecules (hTBM, hEPCR), and factors regulating innate immunity and inflammation (hCD47, HO-1), thereby obtaining xenografts with low immunogenicity and high physiological compatibility (10–12). On the recipient side, immunosuppressive regimens centered on anti-CD40 or anti-CD154 monoclonal antibodies have further reduced early antibody- and T cell-mediated damage. Based on these advancements, non-human primate (NHP) models have achieved unprecedented xenotransplant survival. The longest survival time of heterotopic heart transplants reached 945 days (13), that of orthotopic heart transplants reached 9 months (14), and that of kidney transplants reached 758 days (15). Publicly reported follow-up has reached 271 days of xenokidney function, detailed peer-reviewed clinical reporting is still emerging (16, 17).

Despite the advancements, T cell- and antibody-mediated rejection continues to hinder the clinical application of xenotransplantation (18, 19). This suggests that when hyperacute rejection is effectively managed, adaptive immune responses will become the main factor in xenotransplant outcomes (18, 19). T cells play a core role in this process. As a key bridge between innate and adaptive immunity, conventional αβ T cells cannot only directly attack the graft but also promote antibody responses as well as the recruitment and activation of innate cytotoxic cells via cytokine production. Compared with the limited HLA mismatch in allogeneic transplantation, the extensive species antigenic differences between humans and pigs make the T cell response in xenotransplantation more complex and intense (19–21). Human αβ T cells respond to porcine aortic endothelial cells (PAECs) exhibit more vigorous cell proliferation and cytokine production than they do to human umbilical vein endothelial cells (HUVECs) (22). It has been reported that approximately 0.1% to 10% of peripheral αβ T cells are alloreactive (23–25). Notably, the frequency of xenogeneic donor-reactive T cell clones (XDRTCCs) before transplantation was less than 0.1%, but after kidney xenotransplantation, XDRTCCs rapidly expanded in the peripheral blood (26). Although T cells are typically classified as a component of the adaptive immune response, γδ T cells exhibit characteristics of both innate and adaptive immunity (27, 28). In xenotransplantation, it is evident that certain γδ T cell TCR clones experience substantial clonal expansion (29). These results suggest that although xenotransplantation shares many molecular features with allografts, the resulting T-cell response is usually more intense and develops more rapidly.

This review not only summarizes the current state of scientific research on T-cell immune responses in xenotransplantation but also delves into key strategies aimed at overcoming these immunological challenges.

 Mechanisms of T cell recognition

In xenotransplantation, T cell-mediated rejection reactions require recipient T cells to recognize porcine xenogenic antigens. Understanding these immunological mechanisms is crucial for developing of gene editing strategies for donor pigs and advancing therapeutic drugs aimed at mitigating rejection. Below, we will discuss research advances in understanding the T cell recognition mechanism in xenotransplantation.

Direct pathway

Human T cell receptors (TCRs) are capable of binding to swine leukocyte antigen (SLA) I and II molecules on professional antigen-presenting cells or non-professional antigen-presenting cells of pigs (30–32) (Figure 1A). Donor passenger leukocytes are rapidly cleared after xenotransplantation—largely through macrophage-mediated innate immunity (for example, owing to CD47–SIRPα incompatibility)—thereby confining direct T-cell priming to the early post-transplant period and promoting a subsequent shift toward indirect and semi-direct pathways (21, 33–35). Nevertheless, graft vascular endothelial cells persist and can act as non-professional antigen-presenting cells, supporting local antigen presentation and episodic re-stimulation of infiltrating T cells. In a 61-day pig-to-human decedent model, combined direct and indirect mixed lymphocyte reaction (MLR) were used to define XDRTCCs. Across all time points, a substantial fraction of detected CD4+ XDRTCCs were directly xenoreactive, whereas a smaller fraction showed indirect reactivity; notably, the proportion of directly xenoreactive CD8+ XDRTCCs increased from 15% before transplantation to 73% by postoperative day 49 (26). In a porcine lung allotransplantation model (36), lentiviral vectors targeting B2M and CIITA through ex vivo lung perfusion significantly downregulated the expression of SLA-I/II in porcine lung grafts and achieved long-term survival without immunosuppression. In xenotransplantation, targeting B2M and CIITA in donor pigs by CRISPR/Cas9 and other methods can almost completely eliminate the expression of SLA-I/II; however, this alone is insufficient to induce stable immune tolerance. Unlike allotransplantation, in which antigenic disparity is largely defined by limited MHC mismatching, SLA constitutes only a subset of xenoantigens. Consequently, although targeted deletion of B2M and CIITA can markedly attenuate or even abrogate direct antigen presentation, recipient T cells can still be activated via indirect recognition and thereby mediate rejection (37–39).

Mechanisms of xenorecognition at the priming stage (Created with BioRender). (A) Pig APCs carry out the initial activation of xenoreactive T cells by presenting complete donor antigen–SLA complexes to human T cells (direct pathway). (B) Human APCs carry out the initial activation of xenoreactive T cells by presenting complete donor antigen–HLA complexes to human T cells (indirect pathway). (C) PECs secrete EVs that express SLA. These EVs can directly present antigen-SLA complexes to human T cells in an APC-independent manner (semi-direct pathway). APCs, antigen-presenting cells; SLA, swine leukocyte antigen; TCR, T cell receptor; HLA, human leukocyte antigen; PECs, porcine vascular endothelial cells; EVs, extracellular vesicles.

Three labeled diagrams compare xeno-reactive T cell activation pathways. Panel A shows a porcine antigen-presenting cell (APC) activating a naive T cell via the SLA–TCR interaction. Panel B shows a human APC using the HLA–TCR interaction. Panel C illustrates a porcine extracellular vesicle (EV) with xeno-antigen, SLA–TCR interaction, co-stimulatory molecules (pCD40, pCD80/86, pICAM-1), and an arrow to porcine endothelial cells (PEC), depicting effector T cell formation. Indirect pathway

The indirect antigen recognition pathway in xenotransplantation is essentially the same as that in allogeneic transplantation (Figure 1B). Both involve the processing of donor antigens by the recipient antigen-presenting cells (APCs) and their presentation to T cells via the recipient MHC (40, 41). In xenotransplantation, the indirect recognition faces a highly heterogeneous xeno-peptide library. Studies have shown that the indirect pathway is more advantageous in triggering xenogeneic reactions than allogeneic reactions (42). Bühler group directly quantified this in the pig cell/organ to baboon model using ELISPOT. The direct T cell xenoreaction diminished rapidly over time, whereas the CD4+ T cells response activated by the indirect pathway could be detected for a long time and was associated with pathological damage to the graft (21).

 Semi-direct pathway

Previous studies have demonstrated that the APCs of the donor can release extracellular vesicles (EVs) (43–45). These EVs carry antigen-MHC complexes, co-stimulatory proteins, and adhesion molecules (44, 46). Once the recipient APCs obtain these extracellular vesicles, they can present them as intact molecules to the T cells (46, 47). This pathway is called the semi-direct antigen presentation pathway. When vascular injury, rejection, or thrombosis occurs, human endothelial cells release EVs. These EVs account for 15% of circulating EVs (48). Porcine vascular endothelial cells (PECs) can release extracellular vesicles expressing SLA-I and SLA-DR (49). However, only EVs expressing SLA-I can bind to human CD14+, CD4+, and CD8+ cells. Unlike the traditional semi-direct antigen recognition pathway, although CD14+ monocytes can be modified by EVs expressing SLA-I, these EV-pulsed CD14+ monocytes cannot promote T cell proliferation (49). These endothelium-derived EVs directly initiate the immune response of recipient T cells through SLA-peptide complexes and co-stimulatory molecules. This non-traditional semi-direct pathway is also referred to as the “secondary-direct” pathway (Figure 1C). Reducing or eliminating the expression of SLA may be a method to alleviate the immune response induced by extracellular vesicles (49).

 T-cell co-stimulatory and co-inhibitory pathways

After T cells recognize porcine xenogenic antigens via the direct antigen recognition pathway, porcine co-stimulatory molecules are still capable of cross-species interaction with the corresponding receptors on the surface of human T cells (Figure 2). In contrast to humans, porcine APCs, including dendritic cells and endothelial cells, are capable of continuously expressing pCD80/CD86 (50–53). pCD86 can promote the proliferation of human T cells and IL-2 secretion. Moreover, the co-stimulatory effect of pCD86 on human T cells can be blocked by the human CTLA4Ig fusion protein (52). The CD40-CD154 axis plays an important role in the interaction between T cells and APCs as well as the activation of vascular endothelial cells. Human CD154 can stimulate porcine endothelial cells to induce the expression of MCP-1, IL-8, IP-10, and RANTES (54). When human T cells are co-cultured with PECs, the inflammatory cytokines produced by the human T cells (especially TNF-α, IL-1β, but not IFN-γ) can directly act on PECs, upregulating SLA-I/II, E-selectin, VCAM-1, and ICAM-1 molecules. The expression of these porcine adhesion molecules can recruit human T cells through L-selectin, VLA-4, and LFA-1, thereby promoting the rejection reaction (55–58). Through sequence homology analysis and structural analysis, the structure level supports pCD58 as the functional ligand of human CD2. In terms of co-inhibitory molecules, the porcine PD-L1 has a 73.8% sequence homology with human PD-L1 and has a similar molecular structure. The porcine PD-L1 can inhibit the proliferation of human CD4+ T cells by anti-CD3 and anti-CD28 and promote their apoptosis (59). Soluble porcine LAG-3 can bind to porcine and human MHC II molecules, and has an inhibitory effect on the proliferation of human lymphocytes in the human-porcine mixed lymphocyte reaction (60). As the direct antigen recognition pathway diminishes, the APC of the human can still continuously uptake, process, and present xenogenic antigens (61). The T cells activated by the indirect antigen recognition pathway exhibit co-stimulatory and co-inhibitory pathways that are molecularly similar to those found in allogeneic transplantation (40). However, they exhibit characteristics specific to xenotransplantation in terms of response intensity (62). From the perspective of molecular pathways, the indirect pathway is mediated by a series of classical co-stimulatory molecules, such as CD80/CD86-CD28/CTLA-4, CD40-CD154, and ICOS-ICOSL (63). These signaling axes act in concert to drive the initiation and maintenance of T cell-dependent B-cell activation. Blocking the CD80/CD86-CD28 pathway can mitigate the antibody response against non-Gal antigens (64, 65). However, its effect on extending graft survival is relatively restricted. In contrast, blocking the CD40-CD154 pathway not only significantly suppresses T cell-mediated and antibody-mediated rejection but has also been demonstrated to be essential for attaining long-term survival in non-human primate xenotransplantation models (13–15, 66).

T cell co-stimulatory pathways, subset differentiation, and effector mechanisms in xenotransplantation. Multiple co-stimulatory ligands present on porcine endothelial cells bind cross-species to their corresponding receptors on human T cells. T cells activated via the pCD80/CD86–CD28 and pCD40–CD154 pathways generate inflammatory cytokines, such as TNF-α and IL-1β; these cytokines upregulate endothelial adhesion molecules (E-selectin, VCAM-1, and ICAM-1) and promote the recruitment of human T cells through L-selectin, VLA-4, and LFA-1, thereby facilitating the rejection reaction. Meanwhile, co-inhibitory pathways including pPD-L1–PD-1, pLAG-3–HLA-II, and pCD80/CD86–CTLA-4 also display cross-species reactivity. T cells activated through the indirect antigen recognition pathway possess co-stimulatory and co-inhibitory pathways similar to those in allografts in terms of molecular composition, such as CD40-CD154 and CD80/CD86-CD28/CTLA-4; however, they exhibit unique characteristics in terms of reaction intensity specific to xenotransplantation. Distinct THs assume a central regulatory function in adaptive immune responses through the secretion of cytokines and the provision of co-stimulatory signals. These signals coordinate and augment the differentiation and function of diverse immune cells, including B cells, phagocytes, neutrophils, NK cells, and CTLs. CTLs induce apoptosis of xeno-graft cells through perforin/granzyme and Fas/FasL pathways and are the principal effector cells in cell-mediated rejection. hAPC, human antigen-presenting cell; PEC, porcine vascular endothelial cell; CTLs, cytotoxic T lymphocytes.

Illustration showing cellular and molecular mechanisms of T cell-mediated immune responses in xenotransplantation. Left panel depicts CD8 T cell activation and cytotoxic targeting of pig cells via perforin, granzyme, and Fas pathways. Central panel presents receptor-ligand interactions for T cell activation, suppression, and adhesion, highlighting key surface molecules. Right panel illustrates CD4 T cell differentiation into various T helper subsets with resulting cytokine-mediated interactions and effects on B cells, NK cells, macrophages, CTLs, and neutrophils. Crosstalk between T cells and other immune subsets

T cells serve as a crucial bridge connecting innate and adaptive immune responses in xenotransplantation and are the main executors of cellular immune rejection (34, 40). CD4+ T cells and CD8+ T cells jointly participate in xenograft damage. CD4+ T cells assist B cells in secreting xenospecific antibodies and activating the innate immune system; they also provide crucial auxiliary signals for the activation, clonal expansion, and differentiation into effector phenotypes of CD8+ cytotoxic T lymphocytes (CTLs) (67, 68). Meanwhile, effector CTLs act as the main executors of cell-mediated rejection, mediating the damage and destruction of the xenograft through direct cytotoxicity (67). Before T cell responses emerge, xenografts typically enter an early inflammatory phase characterized by endothelial activation, dysregulation of the complement and coagulation cascades, and the rapid sequestration of innate immune cells. Within hours to days post-transplantation, neutrophils, monocytes/macrophages, and natural killer (NK) cell are recruited to the graft (12, 69). Beyond mediating immediate tissue and microvascular injury, these innate populations drive T cell activation and effector differentiation by promoting antigen uptake and presentation and the release of pro-inflammatory cytokines such as IL-1β, TNF-α, IL-6, and IFN-γ (34, 70). Th1 secretes cytokines such as IFN-γ, which can promote NK cells activation, drive macrophage polarization to the M1 type, and support the differentiation and effector function of CTLs (56). In a humanized mouse model of xenogeneic islet transplantation, serum levels of IFN-γ, IL-6, and IL-17A increased, and Th17 cells were significantly infiltrated in the graft during the rejection period (71). Th17 recruits neutrophils by secreting IL-17A/F and cooperates to promote M1 polarization of macrophages, thereby amplifying local inflammation (72). Conversely, M1 macrophages secrete IL-12, IL-1β, TNF and IL-6, together with chemokines that bias T cell differentiation towards Th1 and Th17 lineages, establishing a feed-forward circuit that sustains effector T cell recruitment and tissue infiltration (73). In contrast, Th2 possibly participate in xenogeneic antibody-mediated rejection (AMR) and chronic injury by promoting B cell activation and antibody class switching (74). Regulatory T cells (Tregs) can mitigate the rejection response towards porcine islets in humanized mice and NHP, and prolong graft survival (75, 76). Large cohorts of allograft kidney transplantation studies have shown that the frequency and phenotype of T follicular helper cells (Tfh) cells are closely related to donor-specific antibodies (DSA) and AMR, suggesting that they also play an important auxiliary role in xenogeneic humoral immunity (77, 78). Meanwhile, B cells are not only effectors of humoral immunity but also function as highly efficient APCs and amplify inflammatory responses through antibody–complement pathways, thereby sustaining the activation of effector T cells (79, 80). CTLs directly cause graft cell death through cytotoxic effects mediated by granzyme/perforin, FasL-Fas-mediated apoptosis, and the release of inflammatory cytokines (81, 82). In a pig-to-macaque kidney transplantation model, selective depletion of CD4+ T cells rather than CD8+ T cells before transplantation enabled long-term survival, and only chronic antibody rejection symptoms appeared in the late stage. These findings suggest that immune regulation targeting CD4+ T cells or donor gene modification is a key strategy for prolonging graft survival and reducing rejection reactions (83).

 The role of γδ T cells in xenotransplantation

γδ T cells exhibit both innate and adaptive immune characteristics. On the one hand, they express V(D)J rearranged γδ TCRs (29, 84). On the other hand, they co-express multiple NK cell-like activating and inhibitory receptors (85, 86). γδ T cells constitute approximately 1%–10% of CD3+ T cells in peripheral blood (87). Nevertheless, in vitro research has demonstrated that nearly 40% of human γδ T cell clones lyse PECs. This cytotoxicity mainly depends on the perforin–granzyme pathway driven by the γδ TCR–CD3 complex, rather than the Fas-FasL axis (88). In the pig to cynomolgus monkey vascular xenotransplantation model, the proportion of γδ T cells in peripheral blood steadily rises after transplantation, and a substantial number of γδ T cells can be observed infiltrating the graft, accompanied by the expansion of multiple clonal types predominantly dominated by δ1, δ3, or δ7 chains (29). Since γδ T cells are MHC-independent, they may have a role in humoral immunity that surpasses that of traditional αβ T cells, functioning as innate-like TFHs to facilitate the production of xenoreactive antibodies (89, 90). However, researchers inadequately understand the specific function of γδ T cells in xenotransplantation, necessitating more research to optimize immunosuppressive strategies and enhance transplant outcomes.

 Multi-approaches to limit T cell xenoreactivity

Xenotransplantation, once a distant scientific aspiration, now stands on the brink of clinical reality, with numerous clinical reports documenting its progress (Table 1). The present research primarily focuses on overcoming the barriers to xenogeneic immunity and physiological compatibility to enhance graft stability and long-term survival. Gene editing technology is used to obtain xenogeneic grafts with low immunogenicity and high physiological compatibility (15). Immune suppression regimens centered on co-stimulation blockade effectively control rejection reactions (13). Building on these advancements, the pursuit of immune tolerance emerges as the ultimate goal, aiming to harmonize the recipient’s immune system with the xenograft. Thymus transplantation and mixed hematopoietic chimerism promote the establishment of central and peripheral tolerance by continuously presenting xenogeneic antigens in the thymus and periphery. Cell therapy enhances the persistence and stability of tolerance by strengthening peripheral immune regulation and antigen-specific inhibition.

Current clinical experience with pig-to-human xenotransplantation.

Surgery date Type of xenotransplantation Genetic modifications Patient status Immunosuppression Monitoring time References
Sep. 2021 Thymokidney transplantation (Outside) GGTA1 KO Brain-dead MMF+MP 54h (69, 91)
NOV. 2021 Thymokidney transplantation (Outside) GGTA1 KO Brain-dead MMF+MP 54h
Sep. 2021 Kidney transplantation 4KO (GGTA1, CMAH, B4GALNT2, GHR) + 6KI (hDAF, hCD46, hTBM, hEPCR, hCD47, hHO1) Brain-dead rATG + Anti-CD20mAb(Rituximab) + TAC + MMF + MP 74h (92–96)
– Kidney transplantation 4KO (GGTA1, CMAH, B4GALNT2, GHR) + 6KI (hDAF, hCD46, hTBM, hEPCR, hCD47, hHO1) Brain-dead rATG + Anti-CD20mAb(Rituximab) + TAC + MMF + MP/Pred + Anti-C5mAb(Eculizumab) 3d
– Kidney transplantation 4KO (GGTA1, CMAH, B4GALNT2, GHR) + 6KI (hDAF, hCD46, hTBM, hEPCR, hCD47, hHO1) Brain-dead rATG + Anti-CD20mAb(Rituximab) + TAC + MMF + MP/Pred + Anti-C5mAb(Eculizumab) 7d
Nov. 2022 Kidney transplantation 3KO (GGTA1, CMAH, B4GALNT2) + hDAF KI Brain-dead rATG + Anti-CD20mAb(Rituximab) + TAC + MMF + MP 12d (8)
Jun.2023 Kidney transplantation 3KO (GGTA1, CMAH, B4GALNT2) + 2KI(hDAF, hTBM) Brain-dead rATG + Anti-CD20mAb(Rituximab) + TAC + MMF + MP + + Anti-C5mAb(Eculizumab) 12d
Jan. 2022 Heart transplantation 4KO (GGTA1, CMAH, B4GALNT2, GHR) + 6KI (hDAF, hCD46, hTBM, hEPCR, hCD47, hHO1) Living rATG + Anti-CD40mAb(KPL-404) + MP + C1INH(Berinert) + Plasmapheresis + IVIG 60d (10, 97)
Jun. 2022 Heart transplantation 4KO (GGTA1, CMAH, B4GALNT2, GHR) + 6KI (hCD59, hCD46, hTBM, hEPCR, hCD47, hHO1) Brain-dead rATG + MMF + MP + Anti-C5mAb(Eculizumab) 66h (98, 99)
Jul. 2022 Heart transplantation 4KO (GGTA1, CMAH, B4GALNT2, GHR) + 6KI (hCD59, hCD46, hTBM, hEPCR, hCD47, hHO1) Brain-dead rATG + MMF + MP + Anti-C5mAb(Eculizumab) 66h
Jul.2023 Thymokidney transplantation GGTA1 KO Brain-dead rATG + Anti-CD20mAb(Rituximab) + CTLA4-Ig(Belatacept)+ TAC + MMF + MP/Pred + Anti-C5mAb(Eculizumab)/C3 inhibitor(Pegcetacoplan) + Plasmapheresis 61d (26, 100)
Sep. 2023 Heart transplantation 4KO (GGTA1, CMAH, B4GALNT2, GHR) + 6KI (hDAF, hCD46, hTBM, hEPCR, hCD47, hHO1) Living Anti-CD154mAb(Tegoprubart)+ C1INH(Berinert)/Anti-C5mAb(Eculizumab) 40d (101)
Mar. 2024 Heterotopic auxiliary liver transplant 3KO (GGTA1, CMAH, B4GALNT2) + 3KI (hDAF, hCD46+ hTBM) Brain-dead rATG + Anti-CD20mAb(Rituximab) + CTLA4-Ig(Etanercept) + TAC + MMF + MP + Anti-C5mAb(ravulizumab) + Plasmapheresis + IVIG 10d (102, 103)
Mar. 2024 Kidney transplantation 3KO (GGTA1, CMAH, B4GALNT2) + 2KI (hDAF, hTBM) Brain-dead rATG + Anti-CD20mAb(Rituximab) + TAC + MMF + MP + Anti-C5mAb(Eculizumab) + Plasmapheresis + IVIG 22d (104)
Mar. 2024 Kidney transplantation 3KO (GGTA1, CMAH, B4GALNT2) + 7KI (hDAF, hCD46, hTBM, hEPCR, hCD47, hTNFAIP3, hHO1) + PERV KO Living rATG + Anti-CD20mAb(Rituximab) + Anti-CD154mAb(Tegoprubart)+ TAC + MMF + Pred + Anti-C5mAb(Eculizumab) 52d (105)
May. 2024 lung transplantatio 3KO (GGTA1, CMAH, B4GALNT2) + 3KI (hDAF, hCD46+ hTBM) Brain-dead rATG + Anti-CD20mAb(Rituximab) + Anti-CD25mAb(Basiliximab) + CTLA4-Ig(Belatacept) + TAC + MMF + MP + Anti-C5mAb(ravulizumab) 9d (11)
Jan. 2025 Kidney transplantation 3KO (GGTA1, CMAH, B4GALNT2) + 7KI (hDAF, hCD46, hTBM, hEPCR, hCD47, hTNFAIP3, hHO1) + PERV KO Living – 271d –
Mar. 2025 Kidney transplantation 3KO (GGTA1, CMAH, B4GALNT2) + 3KI (hDAF, hCD46+ hTBM) Living – 261d –
May. 2025 Auxiliary partial orthotopic liver transplantation 3KO (GGTA1, CMAH, B4GALNT2) + 7KI (hDAF, hCD46, CD59, CD39, hTBM, hEPCR, hCD47) Living Anti-CD20mAb(Rituximab) + Anti-CD25mAb(Basiliximab) + TAC + Sirolimus+ MMF + MP + Anti-C5mAb(ravulizumab) + Plasmapheresis + IVIG 171d(38d remove graft) (106)
Jun. 2025 Kidney transplantation 3KO (GGTA1, CMAH, B4GALNT2) + 7KI (hDAF, hCD46, hTBM, hEPCR, hCD47, hTNFAIP3, hHO1) + PERV KO Living – >181d –
Genetic strategy

Xenotransplantation faces significant challenges due to the stark antigenic differences between pig and human cells. These differences often lead to robust rejection reactions, both antibody-mediated and T-cell-mediated (107, 108). Knocking out (KO) surface carbohydrate antigens GGTA1, CMAH, and B4GALNT2 significantly reduces the pre-existing anti-pig antibodies in human and NHP sera, effectively lowering the incidence of antibody-mediated rejection (109–111). However, compared with WT pigs, GGTA1 knockout (GTKO) reduces human T cell proliferation in MLR, but there is no statistical difference compared with 3KO pigs (112, 113). Both GGTA1/CMAH/B4GALNT2/CIITA and GGTA1/B2M/CIITA knockout pigs exhibited reduced human T-cell proliferation and cytotoxic activation in MLR, indicating that down-regulation of SLA expression can alleviate the direct pathway response of T cells (37, 38). Because the SLA-I of pigs are difficult to interact with human CD94/NKG2A, the inhibitory signals of NK cells, CTLs and γδ T cells cannot be effectively triggered (41, 107, 114). This leads to an enhanced direct cytotoxic response against porcine cells. Introducing human HLA-E or HLA-G into porcine cells can partially restore these inhibitory pathways, thereby reducing the direct cytotoxicity of these cells (115–117). Meanwhile, downregulation of SLA expression in donor pigs can impair T-cell development and compromise antimicrobial immunity, thereby increasing susceptibility to infection and feeding under barrier conditions (37). Although current donor engineering has largely focused on deleting the major carbohydrate xenoantigens (GGTA1, CMAH and B4GALNT2) and modulating SLA expression (for example, via B2M and CIITA), additional xenoantigens remain potential immune targets, including diverse surface glycoproteins (such as β1 integrin and the transferrin receptor) and extracellular matrix (118, 119). Proteomic profiling of recipient serum reactivity to porcine proteins, together with HLA-I immunopeptidome analysis and epitope-presentation prediction, offers complementary, data-driven approaches to identify novel xenoantigens relevant to xenorecognition (119, 120). Phelps group constructed a porcine cytotoxic T-lymphocyte-associated protein 4 immunoglobulin (CTLA4-Ig), but pCTLA4-Ig had poor binding to human CD80/CD86 and caused fatal infections due to immunodeficiency (121, 122). Interestingly, pig PBMC expressing pCTLA4-Ig could reduce the immune response of hCD4+ T cells in co-culture, but compared with hCTLA4-Ig, the binding of pCTLA4-Ig to hCD80/CD86 was significantly weakened (123). Some groups constructed transgenic pigs expressing hCTLA4-Ig (Abatacept) or its affinity-optimized derivative LEA29Y (Belatacept), which permits sexual reproduction and extends the survival period of xenogeneic grafts in humanized mice and NHP models (124–127). Another similar method is to express hPD-L1 on pig cells, and through the PD-1/PD-L1 pathway, T cell activation can be continuously inhibited locally in the graft and apoptosis induced (128). In vitro experiments, the proliferation response of human CD4+ T cells in a co-culture system with hPD-1-expressing pig APC cells was significantly reduced, and the apoptosis of CD8+ T cells was significantly increased, promoting the expansion of CD25hiFoxp3+ Treg cells (128, 129). Overexpression of hFas in PECs induces marked apoptosis of human T cells and NK cells. Therefore, hFasL also constitutes a promising strategy to reduce cellular rejection in xenotransplantation (130). Notably, extensive genetic modification of donor pigs can be counterproductive, as it may compromise donor physiological fitness and graft viability while increasing the risk of off-target mutagenesis and genomic instability (131).

 Induction and co-stimulation-based immunosuppression

In many NHP xenotransplantation models, immunosuppression protocols adapted from conventional allotransplant practice are associated with limited graft survival and substantial graft injury (132). Given this immunological characteristic, an induction protocol for T cell depletion is usually adopted, with anti-thymocyte globulin (ATG) being the most commonly used drug (20, 132). The preoperative use of ATG can usually maintain T cells at a low level within five weeks after surgery. In a porcine-NHP xenotransplantation model, the use of Anti-CD4Ab instead of Anti-CD8Ab also resulted in long-term survival, suggesting the importance of preoperative depletion of CD4+ T cells (83). In the study of porcine-human xenotransplantation, some groups also used Anti-CD25mAb (Basiliximab), which may inhibit T cell activation and proliferation by blocking the IL-2 pathway (11, 106). CTLA-4Ig can reduce the probability of cell rejection in allogeneic transplantation and induce immune tolerance (133–135). However, in multiple primate animal models, CD40-CD154 pathway blockade (anti-CD154 mAb or anti-CD40 mAb) has been associated with reduced graft T-cell infiltration compared with CTLA-4Ig-based regimens and with attenuated donor-specific antibody formation and antibody-mediated rejection (136, 137). In a 61-day clinical study of brain-dead patients, researchers found that in the immunosuppressive regimen based on CTLA-4Ig, there was a significant expansion of donor-reactive CD8+ T cells in the peripheral blood PBMC in the early stage of transplantation (26). Blocking the CD40-CD154 pathway in patients with acute cellular rejection of kidney transplantation can reverse the high oligoclonality of CD8+ T cells and significantly suppress the Tfh-related CD4+ T cells and B cell germinal center-like responses in the graft (138, 139). It is worth noting that the first-generation IgG1 anti-CD154 antibodies were repeatedly reported to cause thrombotic events in clinical trials, becoming one of the direct reasons for the termination of development. These antibodies can bind to FcγRIIa through their Fc fragment, mediate platelet activation and aggregation, thereby inducing drug-related thrombosis (127, 128). In this context, the new generation of anti-CD154 molecules reduce the risk of thrombosis by weakening the binding of Fc to FcγR. AT-1501/tegoprubart and other new anti-CD154 molecules currently show good tolerance in trials for amyotrophic lateral sclerosis and early transplantation-related trials, and no clear trend of thrombus aggregation has been found in the short-term safety data, but the follow-up time is limited and is not sufficient to completely negate its long-term risks (140, 141). Although Anti-CD154mAb and Anti-CD40mAb have not been approved for commercial use, they have been applied in multiple brain-dead donor models and individual xenotransplantations implemented under compassionate use. In in vitro experiments, Zhang found in MLR that at a low concentration of tacrolimus, the proliferation rate of T cells could be reduced to a minimal level, but rapamycin even at high concentrations only had a moderate inhibitory effect (142). In another in vitro study, Li found that pretreatment of PEC with rapamycin could almost completely eliminate its ability to induce T cell proliferation, and this inhibition could not be reversed by PD-1 blockade, suggesting that mTOR inhibition not only acts directly on T cells, but also reduces the quality and intensity of the xenogeneic T cell response by lowering the immunogenicity remodeling of the pig endothelium (143).

 Mixed hematopoietic chimerism

Mixed haematopoietic chimerism is defined as the coexistence of donor- and recipient-derived haematopoietic cells in a recipient following transplantation of donor haematopoietic stem and progenitor cells. Across rodent models, large-animal studies and clinical experience, it has been associated with the induction of durable, donor-specific allograft tolerance (144). By mixing haematopoietic chimerism, donor-derived APCs can continuously migrate into the thymus, thereby enabling the newly generated T cells of the newborn to undergo negative selection with the donor antigens (145). Yang group discovered in a mouse model of porcine hematopoietic chimeras that the newly generated T cells of the recipients showed a significant decrease in response to donor proliferation, and could accept donor-derived skin grafts, while still having a reaction to third-party antigens, demonstrating typical donor-specific T cell tolerance (146). Receptor macrophages rapidly clear porcine hematopoietic progenitor cells, significantly hindering the formation of mixed chimeras. Transgenic expression of hCD47 inhibits phagocytosis by interacting with SIRPαNOD on murine macrophages, thereby significantly enhancing the engraftment of porcine hematopoietic cells in vivo (147). In NHPs, the Yamada group combined intra-bone bone marrow transplantation (IBBMTx) with non-myeloablative conditioning (bone marrow cell dose: 1.8–5.9 × 109 cells/kg); this approach induced peripheral blood macrochimerism for up to 21 days and bone marrow engraftment detectable for up to 28 days (148, 149). In a baboon porcine lung transplantation study, hCD47-transgenic pigs used as both marrow and lung donors enabled durable macrochimerism exceeding 8 weeks with lower marrow cell doses (<1 × 109 cells/kg) and prolonged lung xenograft survival (150). Notably, both IBBMTx studies reported reductions in anti-pig antibody titres and complement-dependent cytotoxicity, together with cellular hyporesponsiveness in MLR and IFNγ ELISPOT assays, consistent with attenuated anti-pig humoral and cellular immunity (148, 150).

 Thymic transplantation

Transplanting donor pig thymus or vascularized thymic tissue to the recipient enables the T cell precursors of the recipient to undergo positive and negative selection in the pig thymus microenvironment (40). Previous studies on humanized mice have demonstrated that pig thymus can support the generation of human T cells with a diverse T cell receptor repertoire (151, 152). The T cells developed in pig thymus exhibit a specific low response to the donor pig, while retaining the ability to react to third-party pigs and human antigens (151, 153). In large animals, incomplete clearance of T cells may pose challenges in achieving tolerance during thymus transplantation (154). Thymus-plus-kidney grafts (Thymokidneys) can be obtained by performing partial thymectomy on pigs aged 6 to 8 weeks and transplanting autologous thymus tissue under the renal capsule (155). The combined transplantation of vascularized thymic grafts with kidneys enables the thymic tissue to be continuously perfused and participate in the generation of new T cells in the recipient’s body in a physiological manner (156). In recent attempts at pig-to-human kidney xenotransplantation involving brain-dead recipients and patients with end-stage renal failure, researchers have used thymokidneys obtained from GalT-KO pigs. Evidence of recipient thymic development within these grafts supports the feasibility of translating the thymic transplantation strategy from NHP models to the clinical pig-to-human setting (26).

 Cell-based immunomodulatory strategy

Cell therapy based on immunomodulatory cells is gradually regarded as an important supplementary strategy for inducing functional tolerance and alleviating the maintenance of immunosuppression in xenotransplantation. Cynthia purified and expanded pig antigen-specific baboon CD4+CD25hi Treg cells in vitro, and compared with primary Treg cells, the expanded Treg cells could significantly inhibit T cell proliferation responses and cytokine secretion in MLR (157). CD27+ xeno-Tregs exhibit a more regulatory phenotype than CD27- counterparts, as evidenced by the upregulation of Foxp3, CTLA-4 and Helios, and the downregulation of IL-17. When these cells are administered to mice bearing porcine skin grafts, they maintain the normal morphology of the graft tissue with reduced leukocyte infiltration (158). In xenogeneic and cross-species hematopoietic stem cell transplantation-related models, Treg infusion was reported to be able to alleviate acute graft-versus-host disease to some extent and improve the quality of immune reconstitution (159). In NHP models, three rhesus monkeys received autologous polyclonal regulatory T-cell infusions after porcine islet xenotransplantation, and two of them maintained insulin independence for more than 500 days (160). MSCs have multi-directional differentiation potential and significant immunomodulatory and tissue repair capabilities. They can inhibit T and B cell activation through various soluble factors such as PGE2, TGF-β, IL-10, and cell contact, induce Treg expansion, and regulate the differentiation of dendritic cells to a tolerogenic phenotype (161). Pig MSCs can alleviate immunogenicity by knocking out GGTA and expressing human complement regulatory proteins, and can effectively down-regulate human T cells’ response to pig antigens, similar to human MSCs (162). Co-encapsulating pig islets with pig MSCs improved oxygenation and new angiogenesis in rat models and primate models (163). Besides Tregs and MSCs, other cell therapies, such as myeloid-derived suppressor cells (MDSCs) and regulatory macrophages (Mregs), are expected to form a multi-cellular synergistic regulatory network with Tregs and MSCs (164).

 Conclusion

As xenotransplantation technology advances towards clinical application, T cells emerge as both a formidable barrier and a pivotal target for intervention, holding the key to unlocking the full potential of this groundbreaking field. Across pig-to-primate and pig-to-human xenotransplantation models, rejection is closely linked to vigorous T-cell activation, initiated through direct, indirect and semi-direct antigen-recognition pathways. In addition, expansion of donor-reactive T cells in both the periphery and the graft is thought to contribute to xenograft injury (26). Conventional immunosuppressive regimens struggle to achieve stable control of T cell-mediated xenotransplant rejection (132). Donor pig gene editing combined with co-stimulation blockade has fundamentally reshaped the field. Multigene editing markedly reduces graft immunogenicity, and when coupled with blockade of the CD40–CD154 or CD28–B7 pathways, has enabled prolonged xenograft survival in NHP models, with early clinical experience providing supportive evidence for these advances.

Future research should shift from broad T-cell suppression to precise, donor-specific control of xenoreactive T cells. Approaches such as durable mixed hematopoietic chimerism, thymic transplantation and regulatory cell-based therapies aim to promote tolerance by enabling selective deletion of donor-reactive clones and/or their functional regulation. Achieving safe, donor-directed control of T-cell immunity will be crucial for realizing the clinical potential of xenotransplantation.

 Author contributions

ZW: Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review & editing. GL: Conceptualization, Data curation, Visualization, Writing – review & editing.

 Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Sun J Hu C Liang Q Yu Y Wen N Dong J . Comparative efficacy and safety of induction therapy in solid organ transplantation: a systematic review and network meta-analysis. Front Immunol. (2025) 16:1625710. doi: 10.3389/fimmu.2025.1625710, PMID: 40726985 Ghanem OM Pita A Nazzal M Johnson S Diwan T Obeid NR . Obesity, organ failure, and transplantation: a review of the role of metabolic and bariatric surgery in transplant candidates and recipients. Surg Endosc. (2024) 38:4138–51. doi: 10.1007/s00464-024-10930-8, PMID: 38951240 King KL Husain SA Perotte A Adler JT Schold JD Mohan S . Deceased donor kidneys allocated out of sequence by organ procurement organizations. Am J Transplant. (2022) 22:1372–81. doi: 10.1111/ajt.16951, PMID: 35000284 Taber DJ Gordon EJ Myaskovsky L Jesse MT Peipert JD George R . Therapeutic needs in solid organ transplant recipients: The American Society of Transplantation patient survey. Am J Transplant. (2025) 25:2565–77. doi: 10.1016/j.ajt.2025.07.2474, PMID: 40744428 Lewis A Koukoura A Tsianos G-I Gargavanis AA Nielsen AA Vassiliadis E . Organ donation in the US and Europe: The supply vs demand imbalance. Transplant Rev. (2021) 35:100585. doi: 10.1016/j.trre.2020.100585, PMID: 33071161 Loupy A Preka E Chen X Wang H He J Zhang K . Reshaping transplantation with AI, emerging technologies and xenotransplantation. Nat Med. (2025) 31:2161–73. doi: 10.1038/s41591-025-03801-9, PMID: 40659768 Ali A Kemter E Wolf E . Advances in organ and tissue xenotransplantation. Annu Rev Anim Biosci. (2024) 12:369–90. doi: 10.1146/annurev-animal-021122-102606, PMID: 37906838 Wang Y Chen G Pan D Guo H Jiang H Wang J . Pig-to-human kidney xenotransplants using genetically modified minipigs. Cell Rep Med. (2024) 5:101744. doi: 10.1016/j.xcrm.2024.101744, PMID: 39317190 Cooper DKC . A brief history of cross-species organ transplantation. Baylor Univ Med Center Proc. (2012) 25:49–57. doi: 10.1080/08998280.2012.11928783, PMID: 22275786 Griffith BP Goerlich CE Singh AK Rothblatt M Lau CL Shah A . Genetically modified porcine-to-human cardiac xenotransplantation. N Engl J Med. (2022) 387:35–44. doi: 10.1056/NEJMoa2201422, PMID: 35731912 He J Shi J Yang C Peng G Ju C Zhao Y . Pig-to-human lung xenotransplantation into a brain-dead recipient. Nat Med. (2025) 31:3388–93. doi: 10.1038/s41591-025-03861-x, PMID: 40855190 Pan W Zhang W Zheng B Camellato BR Stern J Lin Z . Cellular dynamics in pig-to-human kidney xenotransplantation. Med. (2024) 5:1016–1029.e4. doi: 10.1016/j.medj.2024.05.003, PMID: 38776915 Mohiuddin MM Singh AK Corcoran PC Thomas Iii ML Clark T Lewis BG . Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft. Nat Commun. (2016) 7:11138. doi: 10.1038/ncomms11138, PMID: 27045379 Längin M Mayr T Reichart B Michel S Buchholz S Guethoff S . Consistent success in life-supporting porcine cardiac xenotransplantation. Nature. (2018) 564:430–3. doi: 10.1038/s41586-018-0765-z, PMID: 30518863 Anand RP Layer JV Heja D Hirose T Lassiter G Firl DJ . Design and testing of a humanized porcine donor for xenotransplantation. Nature. (2023) 622:393–401. doi: 10.1038/s41586-023-06594-4, PMID: 37821590 Fieldhouse R . ‘Amazing feat’: US man still alive six months after pig kidney transplant. Nat News. (2025) 645:571–2. doi: 10.1038/d41586-025-02851-w, PMID: 40921872 Tao P Zhou K . Recent progress in pig-to-human kidney xenotransplantation. Front Immunol. (2025) 16:1735113. doi: 10.3389/fimmu.2025.1735113, PMID: 41451219 Zhou Q Li T Wang K Zhang Q Geng Z Deng S . Current status of xenotransplantation research and the strategies for preventing xenograft rejection. Front Immunol. (2022) 13:928173. doi: 10.3389/fimmu.2022.928173, PMID: 35967435 Lu T Yang B Wang R Qin C . Xenotransplantation: current status in preclinical research. Front Immunol. (2020) 10:3060. doi: 10.3389/fimmu.2019.03060, PMID: 32038617 Higginbotham L Ford ML Newell KA Adams AB . Preventing T cell rejection of pig xenografts. Int J Surg. (2015) 23:285–90. doi: 10.1016/j.ijsu.2015.07.722, PMID: 26306770 Buhler L Illigens BM-W Nadazdin O Tena A Lee S Sachs DH . Persistence of indirect but not direct T cell xenoresponses in baboon recipients of pig cell and organ transplants. Am J Transplant. (2016) 16:1917–22. doi: 10.1111/ajt.13695, PMID: 26718119 Murray AG Khodadoust MM Pober JS Bothwell AL . Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28. Immunity. (1994) 1:57–63. doi: 10.1016/1074-7613(94)90009-4, PMID: 7889399 DeWolf S Sykes M . Alloimmune T cells in transplantation. J Clin Invest. (2017) 127:2473–81. doi: 10.1172/JCI90595, PMID: 28628037 DeWolf S Grinshpun B Savage T Lau SP Obradovic A Shonts B . Quantifying size and diversity of the human T cell alloresponse. JCI Insight. (2018) 3:e121256. doi: 10.1172/jci.insight.121256, PMID: 30089728 Duneton C Winterberg PD Ford ML . Activation and regulation of alloreactive T cell immunity in solid organ transplantation. Nat Rev Nephrol. (2022) 18:663–76. doi: 10.1038/s41581-022-00600-0, PMID: 35902775 Montgomery RA Stern JM Fathi F Suek N Kim JI Khalil K . Physiology and immunology of pig-to-human decedent kidney xenotransplant. Nature. (2025) 650(8100):218–29. doi: 10.1038/s41586-025-09847-6, PMID: 41233546 Ribot JC Lopes N Silva-Santos B . γδ T cells in tissue physiology and surveillance. Nat Rev Immunol. (2021) 21:221–32. doi: 10.1038/s41577-020-00452-4, PMID: 33057185 Vantourout P Hayday A . Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol. (2013) 13:88–100. doi: 10.1038/nri3384, PMID: 23348415 Lee S Chung YS Lee KW Choi M Sonn CH Oh WJ . Alteration of γδ T cell subsets in non-human primates transplanted with GGTA1 gene-deficient porcine blood vessels. Xenotransplantation. (2024) 31:e12838. doi: 10.1111/xen.12838, PMID: 38112053 Xu X-C Naziruddin B Sasaki H Smith DM Mohanakumar T . Allele-specific and peptide-dependent recognition of swine leukocyte antigen class i by human cytotoxic t-cell Clones1. Transplantation. (1999) 68:473–9. doi: 10.1097/00007890-199908270-00005, PMID: 10480402 Li P Walsh JR Lopez K Isidan A Zhang W Chen AM . Genetic engineering of porcine endothelial cell lines for evaluation of human-to-pig xenoreactive immune responses. Sci Rep. (2021) 11:13131. doi: 10.1038/s41598-021-92543-y, PMID: 34162938 Ladowski JM Reyes LM Martens GR Butler JR Wang Z-Y Eckhoff DE . Swine leukocyte antigen class II is a xenoantigen. Transplantation. (2018) 102:249–54. doi: 10.1097/TP.0000000000001924, PMID: 28846555 Ide K Wang H Tahara H Liu J Wang X Asahara T . Role for CD47-SIRPα signaling in xenograft rejection by macrophages. Proc Natl Acad Sci USA. (2007) 104:5062–6. doi: 10.1073/pnas.0609661104, PMID: 17360380 Maeda A Kogata S Toyama C Lo P-C Okamatsu C Yamamoto R . The innate cellular immune response in xenotransplantation. Front Immunol. (2022) 13:858604. doi: 10.3389/fimmu.2022.858604, PMID: 35418992 Navarro-Alvarez N Yang Y-G . CD47: a new player in phagocytosis and xenograft rejection. Cell Mol Immunol. (2011) 8:285–8. doi: 10.1038/cmi.2010.83, PMID: 21258362 Figueiredo C Chen-Wacker C Salman J Carvalho-Oliveira M Monthé TS Höffler K . Knockdown of swine leukocyte antigen expression in porcine lung transplants enables graft survival without immunosuppression. Sci Transl Med. (2024) 16:eadi9548. doi: 10.1126/scitranslmed.adi9548, PMID: 39018368 Xu K Yu H Chen S Zhang Y Guo J Yang C . Production of triple-gene (GGTA1, B2M and CIITA)-modified donor pigs for xenotransplantation. Front veterinary Sci. (2022) 9:848833. doi: 10.3389/fvets.2022.848833, PMID: 35573408 Fu R Fang M Xu K Ren J Zou J Su L . Generation of GGTA1-/-β2M-/-CIITA-/- pigs using CRISPR/cas9 technology to alleviate xenogeneic immune reactions. Transplantation. (2020) 104:1566–73. doi: 10.1097/TP.0000000000003205, PMID: 32732833 Hein R Sake HJ Pokoyski C Hundrieser J Brinkmann A Baars W . Triple (GGTA1, CMAH, B2M) modified pigs expressing an SLA class Ilow phenotype-Effects on immune status and susceptibility to human immune responses. Am J Transplant. (2020) 20:988–98. doi: 10.1111/ajt.15710, PMID: 31733031 Sykes M Sachs DH . Progress in xenotransplantation: overcoming immune barriers. Nat Rev Nephrol. (2022) 18:745–61. doi: 10.1038/s41581-022-00624-6, PMID: 36198911 Eisenson DL Hisadome Y Yamada K . Progress in xenotransplantation: immunologic barriers, advances in gene editing, and successful tolerance induction strategies in pig-to-primate transplantation. Front Immunol. (2022) 13:899657. doi: 10.3389/fimmu.2022.899657, PMID: 35663933 Dorling A Lombardi G Binns R Lechler RI . Detection of primary direct and indirect human anti-porcine T cell responses using a porcine dendritic cell population. Eur J Immunol. (1996) 26:1378–87. doi: 10.1002/eji.1830260630, PMID: 8647220 Mastoridis S Londoño M-C Kurt A Kodela E Crespo E Mason J . Impact of donor extracellular vesicle release on recipient cell “cross-dressing” following clinical liver and kidney transplantation. Am J Transplant. (2021) 21:2387–98. doi: 10.1111/ajt.16123, PMID: 32515541 Xu W Boer K Hesselink DA Baan CC . Extracellular vesicles and immune activation in solid organ transplantation: the impact of immunosuppression. BioDrugs. (2025) 39:445–59. doi: 10.1007/s40259-025-00713-5, PMID: 40140222 Benichou G Lancia HH . Intercellular transfer of MHC molecules in T cell alloimmunity and allotransplantation. Biomed J. (2024) 47:100749. doi: 10.1016/j.bj.2024.100749, PMID: 38797478 Aloi N Drago G Ruggieri S Cibella F Colombo P Longo V . Extracellular vesicles and immunity: at the crossroads of cell communication. IJMS. (2024) 25:1205. doi: 10.3390/ijms25021205, PMID: 38256278 Coelho MO Quintas ST Sarmento B De Wever O Castro F . Engineered dendritic cells-derived extracellular vesicles for cancer immunotherapy. J Controlled Release. (2025) 381:113620. doi: 10.1016/j.jconrel.2025.113620, PMID: 40088976 Martínez MC Tesse A Zobairi F Andriantsitohaina R . Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol. (2005) 288:H1004–1009. doi: 10.1152/ajpheart.00842.2004, PMID: 15706036 Li S Anwar IJ Canning AJ Vo-Dinh T Kirk AD Xu H . Xenorecognition and costimulation of porcine endothelium-derived extracellular vesicles in initiating human porcine-specific T cell immune responses. Am J Transplant. (2023) 23:904–19. doi: 10.1016/j.ajt.2023.04.006, PMID: 37054891 Li Y Puebla-Clark L Hernández J Díaz I Mateu E . Development of pig conventional dendritic cells from bone marrow hematopoietic cells. vitro. Front Immunol. (2020) 11:553859. doi: 10.3389/fimmu.2020.553859, PMID: 33162975 Auray G Talker SC Keller I Python S Gerber M Liniger M . High-resolution profiling of innate immune responses by porcine dendritic cell subsets. Vitro vivo. Front Immunol. (2020) 11:1429. doi: 10.3389/fimmu.2020.01429, PMID: 32733474 Maher SE Karmann K Min W Hughes CC Pober JS Bothwell AL . Porcine endothelial CD86 is a major costimulator of xenogeneic human T cells: cloning, sequencing, and functional expression in human endothelial cells. J Immunol. (1996) 157:3838–44. doi: 10.4049/jimmunol.157.9.3838, PMID: 8892613 Davis TA Craighead N Williams AJ Scadron A June CH Lee KP . Primary porcine endothelial cells express membrane-bound B7-2 (CD86) and a soluble factor that co-stimulate cyclosporin A-resistant and CD28-dependent human T cell proliferation. Int Immunol. (1996) 8:1099–111. doi: 10.1093/intimm/8.7.1099, PMID: 8757955 Choi I Kim SD Cho B Kim D Park D Koh HS . Xenogeneic interaction between human CD40L and porcine CD40 activates porcine endothelial cells through NF-kappaB signaling. Mol Immunol. (2008) 45:575–80. doi: 10.1016/j.molimm.2007.06.161, PMID: 17675236 Yang J Cho B Choi I Kim DH Kim SD Koh HS . Molecular characterization of miniature porcine RANTES and its chemotactic effect on human mononuclear cells. Transplantation. (2006) 82:1229–33. doi: 10.1097/01.tp.0000235603.19527.05, PMID: 17102777 Coleman TS Pittman HK Purser SM Haisch CE Verbanac KM . Human T-cell-porcine endothelial cell interactions induce human Th1 cytokines and porcine activation markers. J Surg Res. (2001) 97:184–91. doi: 10.1006/jsre.2001.6151, PMID: 11341797 Jutila MA Kurk S Jackiw L Knibbs RN Stoolman LM . L-selectin serves as an E-selectin ligand on cultured human T lymphoblasts. J Immunol. (2002) 169:1768–73. doi: 10.4049/jimmunol.169.4.1768, PMID: 12165498 Birmele B Thibault G Nivet H Gruel Y Bardos P Lebranchu Y . Human lymphocyte adhesion to xenogeneic porcine endothelial cells: modulation by human TNF-alpha and involvement of VLA-4 and LFA-1. Transpl Immunol. (1996) 4:265–70. doi: 10.1016/s0966-3274(96)80046-3, PMID: 8972555 Jeon D Oh K Oh BC Nam DH Kim CH Park H . Porcine PD-L1: cloning, characterization, and implications during xenotransplantation. Xenotransplantation. (2007) 14:236–42. doi: 10.1111/j.1399-3089.2007.00403.x, PMID: 17489864 Kim S-S Byun H-J Kim S-H Lee H-H Lee SJ Kim SJ . Soluble pig lymphocyte activation gene-3 (LAG-3; CD223) inhibits human-to-pig xenogeneic mixed lymphocyte reaction. Biotechnol Lett. (2010) 32:203–8. doi: 10.1007/s10529-009-0144-9, PMID: 19834647 Puga Yung GL Wakley T Kouklas A Seebach JD . Dendritic cells in xenotransplantation: shaping the cellular immune response toward tolerance. Xenotransplantation. (2025) 32:e70037. doi: 10.1111/xen.70037, PMID: 40243284 Snanoudj R Zuber J Legendre C . Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits. Drugs. (2010) 70:2121–31. doi: 10.2165/11538140-000000000-00000, PMID: 20964456 Pilat N Sayegh MH Wekerle T . Costimulatory pathways in transplantation. Semin Immunol. (2011) 23:293–303. doi: 10.1016/j.smim.2011.04.002, PMID: 21616680 Weaver TA Charafeddine AH Agarwal A Turner AP Russell M Leopardi FV . Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med. (2009) 15:746–9. doi: 10.1038/nm.1993, PMID: 19584865 Boulday G Ashton-Chess J Bernard P Karam G Vie H Moreau A . Association of rapamycin and co-stimulation blockade using anti-B7 antibodies in renal allotransplantation in baboons. Nephrol Dialysis Transplant. (2004) 19:1752–60. doi: 10.1093/ndt/gfh126, PMID: 15069178 Tanemura M Yin D Chong AS Galili U . Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J Clin Invest. (2000) 105:301–10. doi: 10.1172/JCI7358, PMID: 10675356 Hu M Hawthorne WJ Yi S O’Connell PJ . Cellular immune responses in islet xenograft rejection. Front Immunol. (2022) 13:893985. doi: 10.3389/fimmu.2022.893985, PMID: 35874735 Den Bogaerde JV Aspinall R Wang M-W Cary N Lim S Wright L . Induction of long-term survival of hamster heart xenografts in rats. Transplantation. (1991) 52:15–9. doi: 10.1097/00007890-199107000-00003, PMID: 1858142 Loupy A Goutaudier V Giarraputo A Mezine F Morgand E Robin B . Immune response after pig-to-human kidney xenotransplantation: a multimodal phenotyping study. Lancet. (2023) 402:1158–69. doi: 10.1016/S0140-6736(23)01349-1, PMID: 37598688 Lu T-Y Xu X-L Du X-G Wei J-H Yu J-N Deng S-L . Advances in innate immunity to overcome immune rejection during xenotransplantation. Cells. (2022) 11:3865. doi: 10.3390/cells11233865, PMID: 36497122 Lee FT Dangi A Shah S Burnette M Yang Y-G Kirk AD . Rejection of xenogeneic porcine islets in humanized mice is characterized by graft-infiltrating Th17 cells and activated B cells. Am J Transplant. (2020) 20:1538–50. doi: 10.1111/ajt.15763, PMID: 31883299 Bai L Li Y Lu C Yang Y Zhang J Lu Z . Anti-IL-17 inhibits PINK1/parkin autophagy and M1 macrophage polarization in rheumatic heart disease. Inflammation. (2024) 48:870–84. doi: 10.1007/s10753-024-02094-3, PMID: 38977539 Peng M Li N Wang H Li Y Liu H Luo Y . Macrophages: subtypes, distribution, polarization, immunomodulatory functions, and therapeutics. MedComm. (2025) 6:e70304. doi: 10.1002/mco2.70304, PMID: 40717900 Louis K Macedo C Lefaucheur C Metes D . Adaptive immune cell responses as therapeutic targets in antibody-mediated organ rejection. Trends Mol Med. (2022) 28:237–50. doi: 10.1016/j.molmed.2022.01.002, PMID: 35093288 Yi S Ji M Wu J Ma X Phillips P Hawthorne WJ . Adoptive transfer with in vitro expanded human regulatory T cells protects against porcine islet xenograft rejection via interleukin-10 in humanized mice. Diabetes. (2012) 61:1180–91. doi: 10.2337/db11-1306, PMID: 22403295 Thomson AW Sasaki K Ezzelarab MB . Non-human primate regulatory T cells and their assessment as cellular therapeutics in preclinical transplantation models. Front Cell Dev Biol. (2021) 9:666959. doi: 10.3389/fcell.2021.666959, PMID: 34211972 Crotty S . T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity. (2019) 50:1132–48. doi: 10.1016/j.immuni.2019.04.011, PMID: 31117010 Zeng S Crichton ES Ford ML Badell IR . Memory T follicular helper cells drive donor-specific antibodies independent of memory B cells and primary germinal center and alloantibody formation. Am J Transplant. (2023) 23:1511–25. doi: 10.1016/j.ajt.2023.06.006, PMID: 37302575 Rastogi I Jeon D Moseman JE Muralidhar A Potluri HK McNeel DG . Role of B cells as antigen presenting cells. Front Immunol. (2022) 13:954936. doi: 10.3389/fimmu.2022.954936, PMID: 36159874 Yuan Y Cui Y Zhao D Yuan Y Zhao Y Li D . Complement networks in gene-edited pig xenotransplantation: enhancing transplant success and addressing organ shortage. J Transl Med. (2024) 22:324. doi: 10.1186/s12967-024-05136-4, PMID: 38566098 Zhang Z-X Ma Y Wang H Arp J Jiang J Huang X . Double-negative T cells, activated by xenoantigen, lyse autologous B and T cells using a perforin/granzyme-dependent, fas-fas ligand-independent pathway. J Immunol. (2006) 177:6920–9. doi: 10.4049/jimmunol.177.10.6920, PMID: 17082607 Shrestha P Turan A Batra L Gulen AE Sun Z Tan H . Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease. Blood Adv. (2023) 7:2181–95. doi: 10.1182/bloodadvances.2022008495, PMID: 36780582 Kim SC Mathews DV Breeden CP Higginbotham LB Ladowski J Martens G . Long-term survival of pig-to-rhesus macaque renal xenografts is dependent on CD4 T cell depletion. Am J Transplant. (2019) 19:2174–85. doi: 10.1111/ajt.15329, PMID: 30821922 Deseke M Rampoldi F Sandrock I Borst E Böning H Ssebyatika GL . A CMV-induced adaptive human Vδ1+ γδ T cell clone recognizes HLA-DR. J Exp Med. (2022) 219:e20212525. doi: 10.1084/jem.20212525, PMID: 35852466 Silva-Santos B Strid J . Working in “NK mode”: natural killer group 2 member D and natural cytotoxicity receptors in stress-surveillance by γδ T cells. Front Immunol. (2018) 9:851. doi: 10.3389/fimmu.2018.00851, PMID: 29740448 Thompson TW Kim AB Li PJ Wang J Jackson BT Huang KTH . Endothelial cells express NKG2D ligands and desensitize antitumor NK responses. Elife. (2017) 6:e30881. doi: 10.7554/eLife.30881, PMID: 29231815 Sanz M Mann BT Ryan PL Bosque A Pennington DJ Hackstein H . Deep characterization of human γδ T cell subsets defines shared and lineage-specific traits. Front Immunol. (2023) 14:1148988. doi: 10.3389/fimmu.2023.1148988, PMID: 37063856 Rodríguez-Gago M de Heredia A Ramírez P Parrilla P Aparicio P Yélamos J . Human anti-porcine gammadelta T-cell xenoreactivity is inhibited by human FasL expression on porcine endothelial cells. Transplantation. (2001) 72:503–9. doi: 10.1097/00007890-200108150-00024, PMID: 11502983 Caccamo N Battistini L Bonneville M Poccia F Fournié JJ Meraviglia S . CXCR5 identifies a subset of Vγ9Vδ2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. J Immunol. (2006) 177:5290–5. doi: 10.4049/jimmunol.177.8.5290, PMID: 17015714 Horner AA Jabara H Ramesh N Geha RS . γ/δ T lymphocytes express CD40 ligand and induce isotype switching in B lymphocytes. J Exp Med. (1995) 181:1239–44. doi: 10.1084/jem.181.3.1239, PMID: 7869041 Montgomery RA Stern JM Lonze BE Tatapudi VS Mangiola M Wu M . Results of two cases of pig-to-human kidney xenotransplantation. N Engl J Med. (2022) 386:1889–98. doi: 10.1056/NEJMoa2120238, PMID: 35584156 Porrett PM Orandi BJ Kumar V Houp J Anderson D Cozette Killian A . First clinical-grade porcine kidney xenotransplant using a human decedent model. Am J Transplant. (2022) 22:1037–53. doi: 10.1111/ajt.16930, PMID: 35049121 Jones-Carr ME Fatima H Kumar V Anderson DJ Houp J Perry JC . C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation. J Clin Invest. (2024) 134:e175996. doi: 10.1172/JCI175996, PMID: 38269581 Cheung MD Asiimwe R Erman EN Fucile CF Liu S Sun C-W . Spatiotemporal immune atlas of a clinical-grade gene-edited pig-to-human kidney xenotransplant. Nat Commun. (2024) 15:3140. doi: 10.1038/s41467-024-47454-7, PMID: 38605083 Anderson DJ Jones-Carr M Perry J Kumar V Porrett PM Locke JE . Genetically modified porcine kidneys have sufficient tissue integrity for use in pig-to-human xenotransplantation. Ann Surg. (2024) 280:374–82. doi: 10.1097/SLA.0000000000006380, PMID: 38842179 Fatima H Eltoum I-E Kumar V Anderson DJ Locke JE . Immunofluorescence and electron microscopy in genetically engineered pig-to-human kidney xenotransplantation: A case report. Am J Kidney Dis. (2025) 86:563–9. doi: 10.1053/j.ajkd.2025.04.021, PMID: 40675320 Mohiuddin MM Singh AK Scobie L Goerlich CE Grazioli A Saharia K . Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report. Lancet. (2023) 402:397–410. doi: 10.1016/S0140-6736(23)00775-4, PMID: 37393920 Moazami N Stern JM Khalil K Kim JI Narula N Mangiola M . Pig-to-human heart xenotransplantation in two recently deceased human recipients. Nat Med. (2023) 29:1989–97. doi: 10.1038/s41591-023-02471-9, PMID: 37488288 Schmauch E Piening B Mohebnasab M Xia B Zhu C Stern J . Integrative multi-omics profiling in human decedents receiving pig heart xenografts. Nat Med. (2024) 30:1448–60. doi: 10.1038/s41591-024-02972-1, PMID: 38760586 Schmauch E Piening BD Dowdell AK Mohebnasab M Williams SH Stukalov A . Multi-omics analysis of a pig-to-human decedent kidney xenotransplant. Nature. (2025) 650:205–17. doi: 10.1038/s41586-025-09846-7, PMID: 41233547 Griffith BP Grazioli A Singh AK Tully A Galindo J Saharia KK . Transplantation of a genetically modified porcine heart into a live human. Nat Med. (2025) 31:589–98. doi: 10.1038/s41591-024-03429-1, PMID: 39779924 Tao K-S Ling Y-W Zhang X Yang Z-X Zhang H-T Yue S-Q . Immune cell landscape in a human decedent receiving a pig liver xenograft. Nat Med. (2025) 31:2611–21. doi: 10.1038/s41591-025-03860-y, PMID: 40739423 Tao K-S Yang Z-X Zhang X Zhang H-T Yue S-Q Yang Y-L . Gene-modified pig-to-human liver xenotransplantation. Nature. (2025) 641:1029–36. doi: 10.1038/s41586-025-08799-1, PMID: 40140580 Ma S Qi R Han S Li Z Zhang X Wang G . Plasma exchange and intravenous immunoglobulin prolonged the survival of a porcine kidney xenograft in a sensitized, brain-dead human recipient. Chin Med J. (2025) 138:2293–307. doi: 10.1097/CM9.0000000000003338, PMID: 39420636 Kawai T Williams WW Elias N Fishman JA Crisalli K Longchamp A . Xenotransplantation of a porcine kidney for end-stage kidney disease. N Engl J Med. (2025) 392:1933–40. doi: 10.1056/NEJMoa2412747, PMID: 39927618 Zhang W Xu Q Xu K Jiang R Wang S Zheng M . Genetically engineered pig-to-human liver xenotransplantation. J Hepatol. (2025). doi: 10.1016/j.jhep.2025.08.044, PMID: 41076089 Lei T Chen L Wang K Du S Gonelle-Gispert C Wang Y . Genetic engineering of pigs for xenotransplantation to overcome immune rejection and physiological incompatibilities: The first clinical steps. Front Immunol. (2022) 13:1031185. doi: 10.3389/fimmu.2022.1031185, PMID: 36561750 Habibabady Z McGrath G Kinoshita K Maenaka A Ikechukwu I Elias GF . Antibody-mediated rejection in xenotransplantation: Can it be prevented or reversed? Xenotransplantation. (2023) 30:e12816. doi: 10.1111/xen.12816, PMID: 37548030 Yoon S Lee S Park C Choi H Yoo M Lee SC . An efficacious transgenic strategy for triple knockout of xeno-reactive antigen genes GGTA1, CMAH, and B4GALNT2 from jeju native pigs. Vaccines. (2022) 10:1503. doi: 10.3390/vaccines10091503, PMID: 36146581 Burlak C Paris LL Lutz AJ Sidner RA Estrada J Li P . Reduced binding of human antibodies to cells from GGTA1/CMAH KO pigs. Am J Transplant. (2014) 14:1895–900. doi: 10.1111/ajt.12744, PMID: 24909344 Estrada JL Martens G Li P Adams A Newell KA Ford ML . Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA 1/CMAH/β4Gal NT 2 genes. Xenotransplantation. (2015) 22:194–202. doi: 10.1111/xen.12161, PMID: 25728481 Butler JR Wang Z-Y Martens GR Ladowski JM Li P Tector M . Modified glycan models of pig-to-human xenotransplantation do not enhance the human-anti-pig T cell response. Transpl Immunol. (2016) 35:47–51. doi: 10.1016/j.trim.2016.02.001, PMID: 26873419 Wang Z-Y Morsi M Nguyen HQ Bikhet M Burnette K Ayares D . The human T-cell proliferative response to triple-knockout pig cells in mixed lymphocyte reaction. Xenotransplantation. (2020) 27:e12619. doi: 10.1111/xen.12619, PMID: 32529670 Lopez KJ Cross-Najafi AA Farag K Obando B Thadasina D Isidan A . Strategies to induce natural killer cell tolerance in xenotransplantation. Front Immunol. (2022) 13:941880. doi: 10.3389/fimmu.2022.941880, PMID: 36072599 Abicht J-M Sfriso R Reichart B Längin M Gahle K Puga Yung GL . Multiple genetically modified GTKO/hCD46/HLA-E/hβ2-mg porcine hearts are protected from complement activation and natural killer cell infiltration during ex vivo perfusion with human blood. Xenotransplantation. (2018) 25:e12390. doi: 10.1111/xen.12390, PMID: 29536572 Forte P Baumann BC Weiss EH Seebach JD . HLA-E expression on porcine cells: protection from human NK cytotoxicity depends on peptide loading. Am J Transplant. (2005) 5:2085–93. doi: 10.1111/j.1600-6143.2005.00987.x, PMID: 16095487 Weiss EH Lilienfeld BG Müller S Müller E Herbach N Keler B . HLA-E/human β2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity. Transplantation. (2009) 87:35–43. doi: 10.1097/tp.0b013e318191c784, PMID: 19136889 Badylak SF . Xenogeneic extracellular matrix as a scaffold for tissue reconstruction. Transplant Immunol. (2004) 12:367–77. doi: 10.1016/j.trim.2003.12.016, PMID: 15157928 Byrne GW Stalboerger PG Davila E Heppelmann CJ Gazi MH McGregor HCJ . Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation. Xenotransplantation. (2008) 15:268–76. doi: 10.1111/j.1399-3089.2008.00480.x, PMID: 18957049 Xu H Hu R Dong X Kuang L Zhang W Tu C . ImmuneApp for HLA-I epitope prediction and immunopeptidome analysis. Nat Commun. (2024) 15:8926. doi: 10.1038/s41467-024-53296-0, PMID: 39414796 Phelps CJ Ball SF Vaught TD Vance AM Mendicino M Monahan JA . Production and characterization of transgenic pigs expressing porcine CTLA4-Ig. Xenotransplantation. (2009) 16:477–85. doi: 10.1111/j.1399-3089.2009.00533.x, PMID: 20042047 Vaughan AN Malde P Rogers NJ Jackson IM Lechler RI Dorling A . Porcine CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7. J Immunol. (2000) 165:3175–81. doi: 10.4049/jimmunol.165.6.3175, PMID: 10975832 Koshika T Phelps C Fang J Lee SE Fujita M Ayares D . Relative efficiency of porcine and human cytotoxic T-lymphocyte antigen 4 immunoglobulin in inhibiting human CD4+ T-cell responses co-stimulated by porcine and human B7 molecules. Immunology. (2011) 134:386–97. doi: 10.1111/j.1365-2567.2011.03496.x, PMID: 22043861 Wang Y Yang H-Q Jiang W Fan N-N Zhao B-T Ou-Yang Z . Transgenic expression of human cytoxic T-lymphocyte associated antigen4-immunoglobulin (hCTLA4Ig) by porcine skin for xenogeneic skin grafting. Transgenic Res. (2015) 24:199–211. doi: 10.1007/s11248-014-9833-9, PMID: 25236862 Klymiuk N van Buerck L Bähr A Offers M Kessler B Wuensch A . Xenografted islet cell clusters from INSLEA29Y transgenic pigs rescue diabetes and prevent immune rejection in humanized mice. Diabetes. (2012) 61:1527–32. doi: 10.2337/db11-1325, PMID: 22522620 Bähr A Käser T Kemter E Gerner W Kurome M Baars W . Ubiquitous LEA29Y expression blocks T cell co-stimulation but permits sexual reproduction in genetically modified pigs. PLoS One. (2016) 11:e0155676. doi: 10.1371/journal.pone.0155676, PMID: 27175998 Vabres B Le Bas-Bernardet S Riochet D Chérel Y Minault D Hervouet J . hCTLA4-Ig transgene expression in keratocytes modulates rejection of corneal xenografts in a pig to non-human primate anterior lamellar keratoplasty model. Xenotransplantation. (2014) 21:431–43. doi: 10.1111/xen.12107, PMID: 25040113 Plege A Borns K Baars W Schwinzer R . Suppression of human T-cell activation and expansion of regulatory T cells by pig cells overexpressing PD-ligands. Transplantation. (2009) 87:975–82. doi: 10.1097/TP.0b013e31819c85e8, PMID: 19352115 Ding Q Lu L Zhou X Zhou Y Chou K-Y . Human PD-L1-overexpressing porcine vascular endothelial cells induce functionally suppressive human CD4+CD25hiFoxp3+ Treg cells. J Leukoc Biol. (2011) 90:77–86. doi: 10.1189/jlb.1210691, PMID: 21498584 Tsuyuki S Kono M Bloom ET . Cloning and potential utility of porcine Fas ligand: overexpression in porcine endothelial cells protects them from attack by human cytolytic cells. Xenotransplantation. (2002) 9:410–21. doi: 10.1034/j.1399-3089.2002.01114.x, PMID: 12371937 Duan X Chen C Du C Guo L Liu J Hou N . Homozygous editing of multiple genes for accelerated generation of xenotransplantation pigs. Genome Res. (2025) 35:1167–78. doi: 10.1101/gr.279709.124, PMID: 40044221 Firl DJ Markmann JF . Measuring success in pig to non-human-primate renal xenotransplantation: Systematic review and comparative outcomes analysis of 1051 life-sustaining NHP renal allo- and xeno-transplants. Am J Transplant. (2022) 22:1527–36. doi: 10.1111/ajt.16994, PMID: 35143091 Khan MA Shamma T Altuhami A Ahmed HA Assiri AM Broering DC . CTLA4-Ig mediated immunosuppression favors immunotolerance and restores graft in mouse airway transplants. Pharmacol Res. (2022) 178:106147. doi: 10.1016/j.phrs.2022.106147, PMID: 35227891 Chopra B Sureshkumar KK . Co-stimulatory blockade with belatacept in kidney transplantation. Expert Opin Biol Ther. (2014) 14:563–7. doi: 10.1517/14712598.2014.896332, PMID: 24620724 Gong N Pleyer U Yang J Vogt K Hill M Anegon I . Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. J Gene Med. (2006) 8:459–67. doi: 10.1002/jgm.876, PMID: 16475216 Ezzelarab MB Ekser B Echeverri G Hara H Ezzelarab C Long C . Costimulation blockade in pig artery patch xenotransplantation – a simple model to monitor the adaptive immune response in nonhuman primates. Xenotransplantation. (2012) 19:221–32. doi: 10.1111/j.1399-3089.2012.00711.x, PMID: 22909135 Iwase H Ekser B Satyananda V Bhama J Hara H Ezzelarab M . Pig-to-baboon heterotopic heart transplantation--exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens. Xenotransplantation. (2015) 22:211–20. doi: 10.1111/xen.12167, PMID: 25847282 Shi T Burg AR Caldwell JT Roskin KM Castro-Rojas CM Chukwuma PC . Single-cell transcriptomic analysis of renal allograft rejection reveals insights into intragraft TCR clonality. J Clin Invest. (2023) 133:e170191. doi: 10.1172/JCI170191, PMID: 37227784 Caldwell JT Shi T Burg AR Koby A Roskin KM Peters AL . Co-stimulatory blockade prevents intragraft accrual of class-switched, activated B cells despite failing to prevent T-cell mediated rejection. bioRxiv. (2025). doi: 10.1101/2025.10.24.683156, PMID: 41279540 Miura S Habibabady ZA Pollok F Ma M Rosales IA Kinoshita K . TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival. Am J Transplant. (2023) 23:1182–93. doi: 10.1016/j.ajt.2023.03.025, PMID: 37030662 Kim SC Wakwe W Higginbotham LB Mathews DV Breeden CP Stephenson AC . Fc-silent anti-CD154 domain antibody effectively prevents nonhuman primate renal allograft rejection. Am J Transplant. (2017) 17:1182–92. doi: 10.1111/ajt.14197, PMID: 28097811 Zhang M Feng H Du J Chen S Zhu L Wang Y . Comparative inhibitory effects of tacrolimus, cyclosporine, and rapamycin on human anti-pig xenogeneic mixed lymphocyte reactions. Xenotransplantation. (2024) 31:e12876. doi: 10.1111/xen.12876, PMID: 39031102 Li S Xu H Kirk AD . Modulation of xenogeneic T-cell proliferation by B7 and mTOR blockade of T cells and porcine endothelial cells. Transplantation. (2022) 106:950–62. doi: 10.1097/TP.0000000000003920, PMID: 34387242 Sykes M . Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials. Transplantation. (2009) 87:309–16. doi: 10.1097/TP.0b013e31819535c2, PMID: 19202432 Zuber J Sykes M . Mechanisms of mixed chimerism-based transplant tolerance. Trends Immunol. (2017) 38:829–43. doi: 10.1016/j.it.2017.07.008, PMID: 28826941 Abe M Qi J Sykes M Yang Y-G . Mixed chimerism induces donor-specific T-cell tolerance across a highly disparate xenogeneic barrier. Blood. (2002) 99:3823–9. doi: 10.1182/blood.v99.10.3823, PMID: 11986242 Tena A Kurtz J Leonard DA Dobrinsky JR Terlouw SL Mtango N . Transgenic expression of human CD47 markedly increases engraftment in a murine model of pig-to-human hematopoietic cell transplantation. Am J Transplant. (2014) 14:2713–22. doi: 10.1111/ajt.12918, PMID: 25278264 Tasaki M Wamala I Tena A Villani V Sekijima M Pathiraja V . High incidence of xenogenic bone marrow engraftment in pig-to-baboon intra-bone bone marrow transplantation. Am J Transplant. (2015) 15:974–83. doi: 10.1111/ajt.13070, PMID: 25676635 Yamada K Ariyoshi Y Pomposelli T Takeuchi K . Intra-bone bone marrow transplantation in pig-to-nonhuman primates for the induction of tolerance across xenogeneic barriers. Methods Mol Biol. (2020) 2110:213–25. doi: 10.1007/978-1-0716-0255-3_14, PMID: 32002911 Watanabe H Ariyoshi Y Pomposelli T Takeuchi K Ekanayake-Alper DK Boyd LK . Intra-bone bone marrow transplantation from hCD47 transgenic pigs to baboons prolongs chimerism to >60 days and promotes increased porcine lung transplant survival. Xenotransplantation. (2020) 27:e12552. doi: 10.1111/xen.12552, PMID: 31544995 Nikolic B Gardner JP Scadden DT Arn JS Sachs DH Sykes M . Normal development in porcine thymus grafts and specific tolerance of human T cells to porcine donor MHC. J Immunol. (1999) 162:3402–7. doi: 10.4049/jimmunol.162.6.3402, PMID: 10092795 Shimizu I Fudaba Y Shimizu A Yang Y-G Sykes M . Comparison of human T cell repertoire generated in xenogeneic porcine and human thymus grafts. Transplantation. (2008) 86:601–10. doi: 10.1097/TP.0b013e318182d47a, PMID: 18724231 Kalscheuer H Onoe T Dahmani A Li H-W Hölzl M Yamada K . Xenograft tolerance and immune function of human T cells developing in pig thymus xenografts. J Immunol. (2014) 192:3442–50. doi: 10.4049/jimmunol.1302886, PMID: 24591363 Zhao Y Swenson K Wekerle T Rodriguez-Barbosa JI Arn JS Sykes M . The critical role of mouse CD4+ cells in the rejection of highly disparate xenogeneic pig thymus grafts. Xenotransplantation. (2000) 7:129–37. doi: 10.1034/j.1399-3089.2000.00048.x, PMID: 10961297 Yamada K Shimizu A Ierino FL Utsugi R Barth RN Esnaola N . Thymic transplantation in miniature swine. I. Development and function of the “thymokidney. Transplantation. (1999) 68:1684–92. doi: 10.1097/00007890-199912150-00011, PMID: 10609944 Yamamoto S Lavelle JM Vagefi PA Arakawa H Samelson-Jones E Moran S . Vascularized thymic lobe transplantation in a pig-to-baboon model: a novel strategy for xenogeneic tolerance induction and T-cell reconstitution. Transplantation. (2005) 80:1783–90. doi: 10.1097/01.tp.0000184445.70285.4b, PMID: 16378075 Porter CM Horvath-Arcidiacono JA Singh AK Horvath KA Bloom ET Mohiuddin MM . Characterization and expansion of baboon CD4+CD25+ Treg cells for potential use in a non-human primate xenotransplantation model. Xenotransplantation. (2007) 14:298–308. doi: 10.1111/j.1399-3089.2007.00416.x, PMID: 17669171 Cao L Ma X Zhang J Yang M He Z Yang C . CD27-expressing xenoantigen-expanded human regulatory T cells are efficient in suppressing xenogeneic immune response. Cell Transplant. (2023) 32:9636897221149444. doi: 10.1177/09636897221149444, PMID: 36644879 Barreras H Copsel SN Bader CS Ding Y Wolf D Cash C . Regulatory T cell amelioration of graft-versus-host disease following allogeneic/xenogeneic hematopoietic stem cell transplantation using mobilized mouse and human peripheral blood donors. Transplant Cell Ther. (2023) 29:341. doi: 10.1016/j.jtct.2023.02.015, PMID: 36804930 Shin JS Kim JM Kim JS Min BH Kim YH Kim HJ . Long-term control of diabetes in immunosuppressed nonhuman primates (NHP) by the transplantation of adult porcine islets. Am J Transplant. (2015) 15:2837–50. doi: 10.1111/ajt.13345, PMID: 26096041 Wu X Jiang J Gu Z Zhang J Chen Y Liu X . Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem Cell Res Ther. (2020) 11:345. doi: 10.1186/s13287-020-01855-9, PMID: 32771052 Ezzelarab M Ezzelarab C Wilhite T Kumar G Hara H Ayares D . Genetically-modified pig mesenchymal stromal cells: xenoantigenicity and effect on human T-cell xenoresponses. Xenotransplantation. (2011) 18:183–95. doi: 10.1111/j.1399-3089.2011.00635.x, PMID: 21696448 Vériter S Gianello P Igarashi Y Beaurin G Ghyselinck A Aouassar N . Improvement of subcutaneous bioartificial pancreas vascularization and function by coencapsulation of pig islets and mesenchymal stem cells in primates. Cell Transplant. (2014) 23:1349–64. doi: 10.3727/096368913X663550, PMID: 23461890 Vu PC Dang NM Nguyen VP Jung J Shim J Hwang JH . Pig regulatory macrophages as a donor-derived immune modulators in xenotransplantation. Front Immunol. (2025) 16:1718937. doi: 10.3389/fimmu.2025.1718937, PMID: 41425597

Edited by: Gilles Benichou, Harvard Medical School, United States

Reviewed by: Nianqiao Gong, Huazhong University of Science and Technology, China

Bastien Poitier, Harvard Medical School, United States